The most prevalent cognitive problems in MS are memory and information processing speed, while language remains largely intact [1]. Cognition is not closely related to other disease variables, such as EDSS, MRI abnormalities [2], disease duration, and phenotype [3]. “Although some think that monitoring MRI is a way of understanding cognition, there is not a direct correlation”, Prof. Dawn Langdon (Royal Holloway University of London, United Kingdom) mentioned. “Disease duration is also not a good clue.” Furthermore, self-reporting of cognition is heavily confounded by many psychosocial issues, like depression, anxiety, fatigue, conscientiousness, perceived stress, and self-efficacy [4,5]. “Although the patient’s own perception and understanding of their cognitive difficulties is very important, it is not a good guide to their objective level”, said Prof. Langdon. Appropriate tools for cognitive assessment include the BRB-N, MACFIMS, and BICAMS. For the future, Prof. Langdon thinks that cognitive impairment should be quantified.
Value of cognitive assessment
Given the current limitations, what is the value of cognitive assessment? Firstly, healthcare professionals (HCPs) obtain an objective cognitive status, to separate the problems from fatigue and mood and to determine whether the patient truly has a cognitive deficit. This information enables HCPs to educate patients and encourage a positive lifestyle, and adopt an appropriate interaction style in terms of how to convey information and check understanding. It also allows HCPs to be vigilant to the increased risk of unemployment and other participation issues that MS patients with cognitive deficits are more vulnerable to. Furthermore, these patients are more likely to have falls and driving accidents, and to have poor disease management, including adherence to medication. Finally, this information can alert the HCPs to cognitive decline or relapses [6]. Currently, a number of expert committees advocate that there should be yearly assessment of cognition [7,8].
Benefits for MS patients consists of providing them with the opportunity to make positive lifestyle choices. Cognitive assessments inform people with MS about their condition and gives them the opportunity to engage, for example, in the Brain Health agenda.
- Rao SM, et al. Neurology. 1991;41:685-91.
- Manca R, et al. J Neurol Sci. 2018;388:115-127.
- Brochet B, Ruet A. Front Neurol. 2019;10:261.
- Akbar N, et al. Cogn Behav Neurol. 2011;24:115-21.
- Beier M, et al. Rehabil Psychol. 2015;60:254-62.
- Langdon DW, et al. Mult Scler. 2012;18:891-8.
- Bakirtzis C, et al. Open Neurol J. 2018;12:31-40.
- Kalb R, et al. Mult Scler. 2018;24:1665-1680.
Posted on
Previous Article
« Tumour mutation score is a better predictor than TMB Next Article
Interview with ESMO President Prof. Josep Tabernero »
« Tumour mutation score is a better predictor than TMB Next Article
Interview with ESMO President Prof. Josep Tabernero »
Table of Contents: ECTRIMS 2019
Featured articles
Towards a Comprehensive Assessment of MS Course
Cognitive assessment in MS
Late-breaking: Role for CSF markers in autoimmune astrocytopathies
Targeted therapies for NMOSD in development
Monitoring and Treatment of Progressive MS
Challenges in diagnosing and treating progressive MS
Risk factors for conversion to secondary progressive MS
Transplantation of autologous mesenchymal stem cells
Sustained reduction in disability progression with ocrelizumab
Late-breaking: Myelin-peptide coupled red blood cells
Optimising Long-Term Benefit of MS Treatment
Induction therapy over treatment escalation
Treatment escalation over induction therapy
Influence of age on disease progression
Exposure to DMTs reduces disability progression
Predicting long-term sustained disability progression
Treatment response scoring systems to assess long term prognosis
Safety Assessment in the Post-Approval Phase
Use of clinical registries in phase 4 of DMT
Genes, environment, and safety monitoring in using registries
Risk of hypogammaglobulinemia and rituximab
Determinants of outcomes for natalizumab-associated PML
Serum immunoglobulin levels and risk of serious infections
EAN guideline on palliative care
Pregnancy in the Treatment Era
The maternal perspective: when to stop/resume treatment and risks for progression
Foetal/child perspective: risks related to drug exposure and breastfeeding
Patient awareness about family planning represents a major knowledge gap
Late-breaking: Continuation of natalizumab or interruption during pregnancy
Related Articles
December 9, 2021
Ibudilast reduced retinal atrophy in primary progressive MS
December 20, 2022
Comparing real-world effectiveness of DMTs
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com